• 13 Dec 21

OKYO Pharma highlights ocular pain-reducing potential of drug candidate OK-101

OKYO Pharma highlights ocular pain-reducing potential of drug candidate OK-101

OKYO Pharma Limited | OKYO | 0 0 0%

    • 102 views

 

OKYO Pharma's CEO Gary Jacob says its drug candidate OK-101 which was developed to treat dry eye diseases through its anti-inflammatory mode of action has also shown potent ocular pain reducing properties. He says there's now the potential to treat both pain and inflammation, the most common symptoms of dry eye, with a single drug.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

OKYO Pharma reaches milestone with first patient screening for dry eye disease trial

Companies: OKYO Pharma Limited

Market Report: Airline makers and travel firms fly after Boris reveals road map out of lockdown

Companies: OKYO Pharma Limited

OKYO Pharma to take dry eye disease drug direct into Phase 2 clinical trials

Companies: OKYO Pharma Limited

OKYO Pharma appoints top Beverly Hills surgeon to lead its Scientific Advisory Board

Companies: OKYO Pharma Limited

FTSE creeps higher despite Omicron headlines and hospitality groups despair at WFH government advise

Companies: OKYO Pharma Limited

OKYO Pharma CEO talks promising pre-clinical data for its acute and chronic ocular pain drug

Companies: OKYO Pharma Limited

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top